The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.

This publication has 11 references indexed in Scilit:

• Regulation of the extrinsic pathway system in health and disease: The role of factor VIIa and tissue factor pathway inhibitor
  Thrombosis Research, 1995
• Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin™). An experimental investigation in healthy volunteers
  Blood Coagulation & Fibrinolysis, 1994
• Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (logiparin), a low molecular weight heparin, in dogs
  Xenobiotica, 1993
• Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
  New England Journal of Medicine, 1992
• Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation
  Thrombosis Research, 1991
• The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor
  Thrombosis Research, 1991
• Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin
  British Journal of Surgery, 1991
• Heparin-, dextran sulfate- and protamine-induced release of extracellular-superoxide dismutase to plasma in pigs
  Biochimica et Biophysica Acta (BBA) - General Subjects, 1988
• Heparin induces release of extrinsic: Coagulation pathway inhibitor (EPI)
  Thrombosis Research, 1988
• A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions
  Thrombosis Research, 1987